NCT03395665

Brief Summary

The development and improvement in Preimplantation genetic diagnosis/screening (PGS) in association with the efficacy and security of vitrification and trophectoderm biopsy, more efficient stimulation schemes and laboratory improvements in culture and embryo selection have contributed to high success of the assisted reproductive technologies(ART). Transferring an euploid embryo avoids one of the main reasons of miscarriage and implantation failure ( Rubio et al, 22016) and overcomes one of the most important confounding factors. Usually, the transfer of euploid embryos is performed under standard hormone replacement therapy (HRT) and are referred to as FET-PGS cycles( Frozen embryo transfer). The study of FET-PGS cycles with the transfer of a single euploid blastocyst is the best model for evaluation of the impact of the endometrial preparation . Among factors influencing FET outcomes, patient's age, endometrial preparation, endometrium thickness, endometrial pattern, number and quality of embryos transferred , difficulty at ET, recently P4 have received more attention . The importance of Progesterone (P4) in embryo implantation has been widely studied. P4 plays an important role in endometrial gland formation, embryonic implantation and pregnancy maintenance, both in natural and artificial cycles.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
299

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2014

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2014

Completed
3.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2017

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2018

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

January 4, 2018

Completed
6 days until next milestone

First Posted

Study publicly available on registry

January 10, 2018

Completed
Last Updated

February 28, 2018

Status Verified

February 1, 2018

Enrollment Period

3.9 years

First QC Date

January 4, 2018

Last Update Submit

February 27, 2018

Conditions

Outcome Measures

Primary Outcomes (3)

  • Live birth rate

    Ten months after transfer procedure

  • Miscarriage rate

    Miscarriage was defined as a loss following a positive pregnancy test and/or detectable Gestational sac

    Any pregnancy loss before week 20

  • Pregnancy rate

    6 weeks after transfer procedure

Interventions

Estradiol level measured at previous day of embryo transfer procedure

Progesterone level measured at previous day of embryo transfer procedure

Endometrial thickness measured at previous day of embryo transfer procedure

Eligibility Criteria

Age18 Years - 43 Years
Sexfemale
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

Women who underwent blastocyst trophectoderm biopsy and PGS and frozen-thawed embryo transfers(PGS-FET) performed after the In Vitro Fertilization (IVF) . PGS was implemented as 46-chromosome screening, using array comparative genomic hybridization (aCGH) from Day 5 trophectoderm biopsy. Whole-genome amplification, processing and analyses were performed using the kits, software and protocols for array Comparative Genomic Hybridisation (aCGH) analysis provided by the manufacturer (SurePlex® DNA Amplification System, 24Sure® Microarray Pack, Bluefuse®, Illlumina®).

You may qualify if:

  • Frozen embryo transfer (FET) of at least one single euploid embryo.
  • Estradiol \> 75pg/ml.
  • Progesterone \> 4 ng/ml.
  • Endometrial thickness between 6 mm and 18 mm.

You may not qualify if:

  • Patients with FET of no diagnostic or mosaic embryos, or known uterine abnormality were excluded.
  • Natura cycle protocol.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Obstetrics, Gynaecology and Reproduction Instituto Universitario Dexeus

Barcelona, 08028, Spain

Location

Related Links

MeSH Terms

Conditions

InfertilityAbortion, Spontaneous

Condition Hierarchy (Ancestors)

Genital DiseasesUrogenital DiseasesPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy Complications

Study Design

Study Type
observational
Observational Model
CASE CROSSOVER
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of Reproductive Medicine Service

Study Record Dates

First Submitted

January 4, 2018

First Posted

January 10, 2018

Study Start

January 1, 2014

Primary Completion

December 1, 2017

Study Completion

January 1, 2018

Last Updated

February 28, 2018

Record last verified: 2018-02

Data Sharing

IPD Sharing
Will not share

Locations